Wells Fargo Turns Bullish on Alector, Citing Overlooked Brain Delivery Technology
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Alector grants Genentech exclusive rights to AL050, a brain-penetrant GCase enzyme therapy for Parkinson’s, for $100 million upfront and up to $1.17 billion more.
Alector announces 49% workforce reduction and discontinuation of latozinemab trials after Phase 3 study fails to show clinical benefit in frontotemporal dementia patients.